| | 54965-24-1 Basic information More.. |
| Product Name: | Tamoxifen citrate | | Synonyms: | TAMOXIPHEN;Ethanamine, 2-4-(1Z)-1,2-diphenyl-1-butenylphenoxy-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);TAMOXIFENCITRATE,USP;TAMOXIFEN CITRATE ANTI-ESTROGEN, PROTEI;TomixipheneCitrate;(Z)-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate;(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, citrate (1:1);(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine citrate (1:1) | | CAS: | 54965-24-1 | | MF: | C32H37NO8 | | MW: | 563.64 | | EINECS: | 259-415-2 | | Mol File: | 54965-24-1.mol |  |
Use
Tamoxifen Citrate is a selective estrogen response modifier (SERM), protein kinase C inhibitor and anti-angiogenetic factor. Tamoxifen is a prodrug that is metabolized to active metabolites 4-hydroxytamoxifen (4-OHT) and endoxifen by cytochrome P450 isoforms CYP2D6 and CYP3A4.
Tamoxifen is used for the treatment of invasive breast cancer in men and women, the most common type of breast cancer, following surgery and/or radiation and for preventing invasive breast cancer in women at high risk for developing it. Tamoxifen also is used for the treatment of women following surgery and radiation for a less common type of breast cancer called ductal carcinoma in situ (DCIS or Intraductal Carcinoma). Women who have had DCIS are at high risk for developing invasive breast cancer at a later date, and tamoxifen prevents development of the invasive cancer in almost half of the women during the first five years of treatment.
- Tamo Xifen Citrate
-
- US $0.00 / kg
- 2024-04-19
- CAS:54965-24-1
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20tons
- Tamoxifen citrate
-
- US $1.00 / g
- 2024-04-19
- CAS:54965-24-1
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100kg
- Tamoxifen citrate
-
- US $1.00 / kg
- 2024-04-19
- CAS:54965-24-1
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg
|
|
54965-24-1
Recommend Suppliers |
|